US · Healthcare · Medical Devices
EPS came in at 1.04 against a street estimate of 1.00 — a beat of 4.0%.
Analysts rate CONMED Corporation a hold (0 buy, 6 hold, 1 sell out of 7) with an average price target of $46.83.
MIXED CONMED delivered solid organic growth and beat quarterly EPS expectations, but lowered the high end of 2026 sales guidance amid softer OEM sales and non-repeat international order timing. Q3 FY26 International growth was strong, but management said some distributor order timing benefited Q3 and will not be underwritten for Q4. Analysts focused on the lower sales outlook, OEM smoke evacuation variability, U.S. orthopedic recovery and AirSeal’s expansion priorities. Management attributed the guide change mainly to FX, GI assumptions and non-recurring international order timing. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.18% |
| Earnest Partners LLC | 8.41% |
| Vanguard Portfolio Management, LLC | 7.34% |
| Fuller & Thaler Asset Management Inc | 5.30% |
| State Street Corp | 4.76% |
| Vanguard Capital Management, LLC | 4.55% |
| Bank of America Corp | 4.50% |
| Dimensional Fund Advisors, Inc. | 4.42% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $335,557, compared with $337,926 in the third quarter of 2025, a decrease of $2,369. • Nine-mon | 2026-10-28 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 sales were $335.6 million, down 0.7% year over year as reported and down 0.8% on a constant-currency basis. • | 2026-10-28 |
| Quarterly report · Q2 2026 CONMED CORPORATION - Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net sales Q2 2026: $343.5 million (vs. $342.3 million Q2 2025) - essentially flat | 2026-07-29 |
| Results announced · Q3 2026 CONMED CORPORATION - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $343.5 million, up 0.3% year-over-year as reported; down 0.5% on | 2026-07-29 |
| Board / officer change · Q2 2026 CONMED CORPORATION FORM 8-K SUMMARY HEADLINE NUMBERS • New CFO appointment effective July 15, 2026: John E. Gallagher joins as Executive Vice Presid | 2026-06-17 |
| Material agreement · Q2 2026 CONMED CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company agreeing to repurchase approximately $645.2 million in aggregate principal amount o | 2026-06-04 |
| Material agreement · Q2 2026 CONMED CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • New debt facility: $450 million in incremental senior secured delayed draw Term A-2 Loan Fa | 2026-06-01 |
| Quarterly report · Q1 2026 CONMED CORPORATION – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net sales: $317.0 million (Q1 2026) vs. $321.3 million (Q1 2025) – down | 2026-04-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CONMED Corporation — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.